摘要
目的：探讨 CC 族趋化因子受体9（ C-C chemokine receptor 9, CCR9）在非小细胞肺癌（ non-small cell lung cancer, NSCLC）中的表达及其预后判断的价值。方法应用免疫组化PV-9000两步法检测119例NSCLC及相应癌旁正常肺组织中CCR9蛋白的表达,并分析CCR9表达与临床病理特征及患者总生存率的关系。结果 CCR9在NSCLC中的阳性率（54.6%）明显高于癌旁正常肺组织（10．1%）（ P 〈0．05）；CCR9表达与 NSCLC 病理组织类型、淋巴结转移、p-TNM 分期有关（ P 〈0．05）。 Kaplan-Meier生存分析显示肺癌中CCR9蛋白表达与患者术后总生存率呈负相关（Log-rank=9．917,P=0．002）。单因素生存分析显示,淋巴结转移、p-TNM分期、CCR9蛋白表达与NSCLC患者术后总生存率有关（ P〈0．05）。多因素生存分析显示,CCR9是NSCLC患者术后总生存率的独立预测因素（RR=0．447,95%CI：0．201～0．993,P〈0．05）。结论 CCR9阳性患者预后较差,其可作为NSCLC患者预后判断的新生物学标志物。
Purpose To investigate the expression of C-C chemokine receptor 9 （CCR9） in non-small cell lung cancer （NSCLC） and to explore its prognostic value. Methods The expression of CCR9 was detected by immunohistochemistry in tumor tissues and corre-sponding adjacent normal tissues from 119 NSCLC patients. Additionally, the correlation between CCR9 expression and the clinicopath-ologic features of NSCLC and the relationship between prognostic factors and overall survival rate were analyzed by statistical methods. Results The positive expression rate of CCR9 was significantly higher in NSCLC tissues （54. 6%） than that in adjacent normal lung tissues （10. 1%） （P〈0. 05）. The expression of CCR9 in NSCLC was correlated with histopathologic type, lymph node status and p-TNM stage （P〈0. 05）. Kaplan-Meier survival analysis suggested that the positive expression of CCR9 was negatively correlated with the overall survival rate （Log-rank=9. 917, P=0. 002）. Univariate analysis showed that the lymph node status, p-TNM stage and the positive expression of CCR9 made great difference to postoperative overall survival （P〈0. 05）. Multivariate analysis showed that CCR9 expression was an independent prognostic factor for overall survival of NSCLC patients （ RR=0. 447, 95%CI：0. 201 ～0. 993, P〈0. 05）. Conclusion The expression of CCR9 may predict a poor prognosis in the patients with NSCLC, so it can be used as a novel NSCLC biomarker.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2015年第7期764-768,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
广西科技厅攻关项目(桂科攻0816004-08)
